Cumulative incidence of, risk factors for, and outcome of dermatological complications of Anti-TNF therapy in inflammatory bowel disease: A 14-year experience

American Journal of Gastroenterology

Volumn 110, Issue 8, 2015, Pages 1186-1196

  Fréling, Estelle ^a   Baumann, Cédric ^a   Cuny, Jean François ^a   Bigard, Marc André ^a   Schmutz, Jean Luc ^a   Barbaud, Annick ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACTINIC KERATOSIS; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BASAL CELL CARCINOMA; CHILD; CROHN DISEASE; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA MULTIFORME; FEMALE; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; RISK FACTOR; SKIN DISEASE; SKIN INFECTION; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; SURVIVAL; TREATMENT OUTCOME; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; DOSE RESPONSE; DRUG ERUPTIONS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SKIN DISEASES, INFECTIOUS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN DISEASES, INFECTIOUS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84939266240     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.205     Document Type: Article

References (43)

1. Clark M, Colombel J-F, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of infl ammatory bowel disease, June 21-23, 2006 Gastroenterology 2007 133 312-339
2. Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Infl amm Bowel Dis 2012; 18: 1641-6
3. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930-6
4. Moustou A-E, Matekovits A, Dessinioti C, et al. Cutaneous side Effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009; 61: 486-504
5. Moran GW, Lim AWK, Bailey JL, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in infl ammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 1002-24
6. Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated infl ammation in infl ammatory bowel disease patients receiving anti-TNF-A agents. Autoimmun Rev 2014; 13: 15-19
7. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance withincreased production of interferon-Alpha in psoriasiform eruptions associated withantitumour necrosis factor-Alpha treatments. Br J Dermatol 2009; 161: 1081-8
8. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-40
9. De Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-Alpha inhibitors in patients withrheumatologic conditions. Arch Dermatol 2007; 143: 223-31
10. Palucka AK, Blanck J-P, Bennett L, et al. Cross-regulation of TNF and IFN-Alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102: 3372-7
11. Piskin G, Sylva-Steenland RMR, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in Healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol Baltim Md 1950 2006; 176: 1908-15
12. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients withinfl ammatory bowel disease are characterised by interferon-? -expressing Th1 cells and IL-17 A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63: 567-77
13. Rahier J-F, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients withinfl ammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol OffClin Pract J Am Gastroenterol Assoc 2010; 8: 1048-55
14. Broge T, Nguyen N, Sacks A, et al. Infl iximab-Associated psoriasis in children withCrohn's disease may require withdrawal of anti-tumor necrosis factor therapy. Infl amm Bowel Dis 2013; 19: 75-7
15. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001
16. Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated withantitumour necrosis factor therapy in infl ammatory bowel disease: a new series and a review of 120 cases from the literature: Anti-TNF-induced psoriasis in infl ammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 1318-27
17. Passarini B, Infusino SD, Barbieri E, et al. Cutaneous manifestations in infl ammatory bowel diseases: eight cases of psoriasis induced by anti-tumornecrosis-factor antibody therapy. Dermatol Basel Switz 2007; 215: 295-300
18. Guerra I, Algaba A, Pérez-Calle JL, et al. Induction of psoriasis withanti-TNF agents in patients withinfl ammatory bowel disease: a report of 21cases. J Crohns Colitis 2012; 6: 518-23
19. Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF-Alpha induced psoriasis in patients withinfl ammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 921-7
20. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infl iximab for the treatment of infl ammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8
21. Afzali A, Wheat CL, Hu JK, et al. The association of psoriasiform rash withanti-tumor necrosis factor (anti-TNF) therapy in infl ammatory bowel disease: a single academic center case series. J Crohns Colitis 2014; 8: 480-8
22. Cleynen I, Vermeire S. Paradoxical infl ammation induced by anti-TNF agents in patients withIBD. Nat Rev Gastroenterol Hepatol 2012; 9: 496-503
23. Mälkönen T, Wikström A, Heiskanen K, et al. Skin reactions during anti-TNFa therapy for pediatric infl ammatory bowel disease: a 2-year prospective study. Infl amm Bowel Dis 2014; 20: 1309-15
24. Torres J, Buche S, Delaporte E, et al. Skin side Effects of infl ammatory bowel disease therapy. Infl amm Bowel Dis 2013; 19: 1086-98
25. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in infl ammatory bowel disease. J Crohns Colitis 2014; 8: 443-68
26. Wetter DA, Davis MDP. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84: 979-84
27. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature withimplications for treatment withalternative TNF alpha antagonists. Int J Dermatol 2011; 50: 619-25
28. De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: 545-51
29. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-Analysis of rare harmful Effects in randomized controlled trials. JAMA 2006; 295: 2275-85
30. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-Alpha-blocking therapy in patients withrheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: 666-76
31. Lee H-H, Song I-H, Friedrich M, et al. Cutaneous side-Effects in patients withrheumatic diseases during application of tumour necrosis factor-A antagonists. Br J Dermatol 2007; 156: 486-91
32. Listing J, Strangfeld A, Kary S, et al. Infections in patients withrheumatoid arthritis treated withbiologic agents. Arthritis Rheum 2005; 52: 3403-12
33. Cabou C, Bagheri H, Cantagrel A, et al. [Retrospective analysis of adverse Effects of infl iximab in a hospital rheumatology service]. Therapie 2003; 58: 457-62
34. Colombel J-F, Loft us EV, Tremaine WJ, et al. The safety profile of infl iximab in patients withCrohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31
35. Baeten D, Kruithof E, Van den Bosch F, et al Systematic safety follow up in a cohort of 107 patients withspondyloarthropathy treated withinfl iximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003 62 829-34
36. Georgala S, Katoulis AC, Kanelleas A, et al. Letter: Human papilloma virus and molluscum contagiosum lesions related to infl iximab therapy for psoriasis: a case series. Dermatol Online J 2012; 18: 9
37. Antoniou C, Kosmadaki MG, Stratigos AJ, et al. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-Alpha therapy. Dermatol Basel Switz 2008; 216: 364-5
38. Somasekar A, Alcolado R. Genital condylomata in a patient receiving infl iximab for Crohn's disease. Postgrad Med J 2004; 80: 358-9
39. Crum NF, Lederman ER, Wallace MR. Infections associated withtumor necrosis factor-Alpha antagonists. Medicine (Baltimore) 2005; 84: 291-302
40. Wendling D, Streit G, Toussirot E, et al. Herpes zoster in patients taking TNFalpha antagonists for chronic infl ammatory joint disease. Jt Bone Spine Rev Rhum 2008; 75: 540-3
41. Van Dartel SAA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients withrheumatoid arthritis treated withadalimumab, infl iximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013; 72: 895-900
42. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008; 372: 67-81
43. Buisson A, Cuny J-F, Barbaud A, et al. Methotrexate for psoriasiform lesions associated withanti-tumour necrosis factor therapy in infl ammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 1175-80